XML 45 R30.htm IDEA: XBRL DOCUMENT v3.19.1
Segments of Business and Geographic Areas (Tables)
 3 Months Ended
Mar. 31, 2019
Segment Reporting [Abstract]  
Sales By Segment Of Business
SALES BY SEGMENT OF BUSINESS
 
 
 
Fiscal First Quarters Ended
(Dollars in Millions)
 
 
March 31,
2019
 
April 1,
2018
 
Percent Change
 
 
 
 
 
 
 
 
CONSUMER
 
 
 
 
 
 
 
Baby Care
 
 
 
 
 
 
 
     U.S.
 
 
$
87

 
97

 
(10.9
)%
     International
 
 
307

 
360

 
(14.8
)
     Worldwide
 
 
394

 
457

 
(14.0
)
Beauty
 
 
 
 
 
 
 
     U.S.
 
 
588

 
611

 
(3.8
)
     International
 
 
502

 
473

 
6.2

     Worldwide
 
 
1,090

 
1,084

 
0.6

Oral Care
 
 
 
 
 
 
 
     U.S.
 
 
151

 
157

 
(3.5
)
     International
 
 
216

 
222

 
(2.8
)
     Worldwide
 
 
367

 
379

 
(3.1
)
OTC
 
 
 
 
 
 
 
     U.S.
 
 
507

 
465

 
9.1

     International
 
 
580

 
607

 
(4.6
)
     Worldwide
 
 
1,087

 
1,072

 
1.3

Women's Health
 
 
 
 
 
 
 
     U.S.
 
 
3

 
3

 
4.2

     International
 
 
222

 
240

 
(7.5
)
     Worldwide
 
 
225

 
243

 
(7.3
)
Wound Care/Other
 
 
 
 
 
 
 
     U.S.
 
 
102

 
103

 
(0.9
)
     International
 
 
53

 
60

 
(11.6
)
     Worldwide
 
 
155

 
163

 
(4.8
)
TOTAL CONSUMER
 
 
 
 
 
 
 
     U.S.
 
 
1,438

 
1,436

 
0.2

     International
 
 
1,880

 
1,962

 
(4.2
)
     Worldwide
 
 
3,318

 
3,398

 
(2.4
)
 
 
 
 
 
 
 
 
PHARMACEUTICAL
 
 
 
 
 
 
 
Immunology
 
 
 
 
 
 
 
     U.S.
 
 
2,163

 
2,000

 
8.1

     International
 
 
1,088

 
1,042

 
4.5

     Worldwide
 
 
3,251

 
3,042

 
6.9

     REMICADE®
 
 
 
 
 
 
 
     U.S.
 
 
774

 
916

 
(15.5
)
     U.S. Exports
 
 
76

 
142

 
(46.4
)
     International
 
 
252

 
331

 
(23.6
)
     Worldwide
 
 
1,102

 
1,389

 
(20.6
)
     SIMPONI / SIMPONI ARIA®
 
 
 
 
 
 
 
     U.S.
 
 
263

 
224

 
17.0

     International
 
 
261

 
294

 
(11.1
)
     Worldwide
 
 
524

 
518

 
1.0

     STELARA®
 
 
 
 
 
 
 
     U.S.
 
 
882

 
652

 
35.2

     International
 
 
523

 
409

 
27.9

     Worldwide
 
 
1,405

 
1,061

 
32.4

     TREMFYA®
 
 
 
 
 
 
 
     U.S.
 
 
168

 
66

 
*
     International
 
 
49

 
6

 
*
     Worldwide
 
 
217

 
72

 
*
     OTHER IMMUNOLOGY
 
 
 
 
 
 
 
     U.S.
 
 
—

 
—

 
—
     International
 
 
3

 
2

 
19.5
     Worldwide
 
 
3

 
2

 
19.5
 
 
 
 
 
 
 
 
Infectious Diseases
 
 
 
 
 
 
 
     U.S.
 
 
357

 
333

 
7.3

     International
 
 
489

 
497

 
(1.7
)
     Worldwide
 
 
846

 
830

 
1.9

     EDURANT® / rilpivirine
 
 
 
 
 
 
 
     U.S.
 
 
12

 
14

 
(18.8
)
     International
 
 
199

 
196

 
2.2

     Worldwide
 
 
211

 
210

 
0.8

     PREZISTA® / PREZCOBIX® / REZOLSTA® / SYMTUZA®
 
 
 
 
 
 
 
     U.S.
 
 
315

 
273

 
15.5

     International
 
 
208

 
205

 
1.5

     Worldwide
 
 
523

 
478

 
9.5

     OTHER INFECTIOUS DISEASES
 
 
 
 
 
 
 
     U.S.
 
 
30

 
46

 
(33.8
)
     International
 
 
82

 
96

 
(16.0
)
     Worldwide
 
 
112

 
142

 
(21.7
)
 
 
 
 
 
 
 
 
Neuroscience
 
 
 
 
 
 
 
     U.S.
 
 
723

 
624

 
16.0

     International
 
 
905

 
935

 
(3.2
)
     Worldwide
 
 
1,629

 
1,559

 
4.5

     CONCERTA® / Methylphenidate
 
 
 
 
 
 
 
     U.S.
 
 
97

 
66

 
47.7

     International
 
 
116

 
107

 
8.5

     Worldwide
 
 
214

 
173

 
23.4

     INVEGA SUSTENNA® / XEPLION® / INVEGA TRINZA® / TREVICTA®
 
 
 
 
 
 
 
     U.S.
 
 
483

 
400

 
20.7

     International
 
 
307

 
296

 
3.8

     Worldwide
 
 
790

 
696

 
13.5

     RISPERDAL CONSTA®
 
 
 
 
 
 
 
     U.S.
 
 
77

 
82

 
(6.8
)
     International
 
 
102

 
114

 
(10.3
)
     Worldwide
 
 
179

 
196

 
(8.8
)
     OTHER NEUROSCIENCE
 
 
 
 
 
 
 
     U.S.
 
 
66

 
76

 
(12.0
)
     International
 
 
379

 
418

 
(9.2
)
     Worldwide
 
 
446

 
494

 
(9.6
)
 
 
 
 
 
 
 
 
Oncology
 
 
 
 
 
 
 
     U.S.
 
 
962

 
933

 
3.1

     International
 
 
1,556

 
1,378

 
13.0

     Worldwide
 
 
2,518

 
2,311

 
9.0

     DARZALEX®
 
 
 
 
 
 
 
     U.S.
 
 
352

 
264

 
33.0

     International
 
 
277

 
168

 
65.1

     Worldwide
 
 
629

 
432

 
45.5

     IMBRUVICA®
 
 
 
 
 
 
 
     U.S.
 
 
349

 
227

 
53.7

     International
 
 
435

 
360

 
20.8

     Worldwide
 
 
784

 
587

 
33.5

     VELCADE®
 
 
 
 
 
 
 
     U.S.
 
 
—

 
—

 
—

     International
 
 
263

 
313

 
(16.0
)
     Worldwide
 
 
263

 
313

 
(16.0
)
     ZYTIGA® / abiraterone acetate
 
 
 
 
 
 
 
     U.S.
 
 
185

 
407

 
(54.5
)
     International
 
 
494

 
438

 
12.9

     Worldwide
 
 
679

 
845

 
(19.6
)
     OTHER ONCOLOGY
 
 
 
 
 
 
 
     U.S.
 
 
76

 
35

 
*

     International
 
 
87

 
99

 
(12.2
)
     Worldwide
 
 
163

 
134

 
21.7

 
 
 
 
 
 
 
 
Pulmonary Hypertension
 
 
 
 
 
 
 
     U.S.
 
 
430

 
361

 
19.2

     International
 
 
226

 
224

 
0.7

     Worldwide
 
 
656

 
585

 
12.1

     OPSUMIT®
 
 
 
 
 
 
 
     U.S.
 
 
172

 
149

 
15.9

     International
 
 
133

 
122

 
8.9

     Worldwide
 
 
306

 
271

 
12.7

     TRACLEER®
 
 
 
 
 
 
 
     U.S.
 
 
61

 
68

 
(10.1
)
     International
 
 
56

 
72

 
(22.9
)
     Worldwide
 
 
117

 
140

 
(16.7
)
     UPTRAVI®
 
 
 
 
 
 
 
     U.S.
 
 
176

 
124

 
41.4

     International
 
 
22

 
16

 
42.8

     Worldwide
 
 
198

 
140

 
41.6

     OTHER 
 
 
 
 
 
 
 
     U.S.
 
 
21

 
20

 
3.6

     International
 
 
15

 
14

 
4.6

     Worldwide
 
 
35

 
34

 
4.0

 
 
 
 
 
 
 
 
Cardiovascular / Metabolism / Other
 
 
 
 
 
 
 
     U.S.
 
 
947

 
1,103

 
(14.1
)
     International
 
 
398

 
414

 
(3.9
)
     Worldwide
 
 
1,345

 
1,517

 
(11.3
)
     XARELTO®
 
 
 
 
 
 
 
     U.S.
 
 
542

 
578

 
(6.3
)
     International
 
 
—

 
—

 
—

     Worldwide
 
 
542

 
578

 
(6.3
)
     INVOKANA® / INVOKAMET®
 
 
 
 
 
 
 
     U.S.
 
 
154

 
204

 
(24.8
)
     International
 
 
49

 
44

 
11.6

     Worldwide
 
 
202

 
248

 
(18.4
)
     PROCRIT® / EPREX®
 
 
 
 
 
 
 
     U.S.
 
 
148

 
189

 
(21.6
)
     International
 
 
78

 
87

 
(10.2
)
     Worldwide
 
 
226

 
276

 
(18.0
)
     OTHER
 
 
 
 
 
 
 
     U.S.
 
 
104

 
132

 
(21.3
)
     International
 
 
271

 
283

 
(4.4
)
     Worldwide
 
 
374

 
415

 
(9.7
)
 
 
 
 
 
 
 
 
TOTAL PHARMACEUTICAL
 
 
 
 
 
 
 
     U.S.
 
 
5,582

 
5,354

 
4.3

     International
 
 
4,662

 
4,490

 
3.9

     Worldwide
 
 
10,244

 
9,844

 
4.1

 
 
 
 
 
 
 
 
MEDICAL DEVICES
 
 
 
 
 
 
 
Diabetes Care
 
 
 
 
 
 
 
     U.S.
 
 
—

 
117

 
*

     International
 
 
—

 
222

 
*

     Worldwide
 
 
—

 
339

 
*

Interventional Solutions
 
 
 
 
 
 
 
     U.S.
 
 
343

 
304

 
12.6

     International
 
 
389

 
336

 
15.8

     Worldwide
 
 
732

 
640

 
14.3

Orthopaedics
 
 
 
 
 
 
 
     U.S.
 
 
1,318

 
1,307

 
0.9

     International
 
 
885

 
943

 
(6.2
)
     Worldwide
 
 
2,204

 
2,250

 
(2.1
)
     HIPS
 
 
 
 
 
 
 
     U.S.
 
 
213

 
209

 
2.1

     International
 
 
148

 
154

 
(3.8
)
     Worldwide
 
 
361

 
363

 
(0.4
)
     KNEES
 
 
 
 
 
 
 
     U.S.
 
 
223

 
228

 
(2.2
)
     International
 
 
146

 
159

 
(8.2
)
     Worldwide
 
 
369

 
387

 
(4.7
)
     TRAUMA
 
 
 
 
 
 
 
     U.S.
 
 
417

 
407

 
2.5

     International
 
 
268

 
289

 
(7.0
)
     Worldwide
 
 
685

 
696

 
(1.4
)
     SPINE & OTHER
 
 
 
 
 
 
 
     U.S.
 
 
465

 
463

 
0.3

     International
 
 
323

 
341

 
(5.5
)
     Worldwide
 
 
788

 
804

 
(2.2
)
Surgery
 
 
 
 
 
 
 
     U.S.
 
 
1,001

 
993

 
0.8

     International
 
 
1,394

 
1,430

 
(2.6
)
     Worldwide
 
 
2,395

 
2,423

 
(1.2
)
     ADVANCED
 
 
 
 
 
 
 
     U.S.
 
 
404

 
393

 
2.9

     International
 
 
576

 
573

 
0.5

     Worldwide
 
 
980

 
966

 
1.5

     GENERAL
 
 
 
 
 
 
 
     U.S.
 
 
425

 
423

 
0.3

     International
 
 
665

 
704

 
(5.6
)
     Worldwide
 
 
1,089

 
1,127

 
(3.4
)
     SPECIALTY
 
 
 
 
 
 
 
     U.S.
 
 
172

 
177

 
(2.5
)
     International
 
 
153

 
153

 
(0.2
)
     Worldwide
 
 
325

 
330

 
(1.4
)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Vision
 
 
 
 
 
 
 
     U.S.
 
 
446

 
440

 
1.5

     International
 
 
682

 
675

 
1.1

     Worldwide
 
 
1,129

 
1,115

 
1.2

     CONTACT LENSES / OTHER
 
 
 
 
 
 
 
     U.S.
 
 
321

 
309

 
4.1

     International
 
 
502

 
498

 
1.0

     Worldwide
 
 
824

 
807

 
2.1

     SURGICAL
 
 
 
 
 
 
 
     U.S.
 
 
125

 
131

 
(4.5
)
     International
 
 
180

 
177

 
1.3

     Worldwide
 
 
305

 
308

 
(1.1
)
 
 
 
 
 
 
 
 
TOTAL MEDICAL DEVICES
 
 
 
 
 
 
 
     U.S.
 
 
3,109

 
3,161

 
(1.6
)
     International
 
 
3,350

 
3,606

 
(7.1
)
     Worldwide
 
 
6,459

 
6,767

 
(4.6
)
 
 
 
 
 
 
 
 
WORLDWIDE
 
 
 
 
 
 
 
     U.S.
 
 
10,129

 
9,951

 
1.8

     International
 
 
9,892

 
10,058

 
(1.7
)
     Worldwide
 
 
$
20,021

 
20,009

 
0.1
 %

*Percentage greater than 100% or not meaningful
Operating Profit by Segment of Business
EARNINGS BEFORE PROVISION FOR TAXES BY SEGMENT
 
 
 
Fiscal First Quarters Ended
(Dollars in Millions)
 
 
March 31,
2019
 
April 1,
2018
 
Percent Change
Consumer (1)
 
 
$
741

 
548

 
35.2
 %
Pharmaceutical(2)
 
 
2,331

 
3,666

 
(36.4
)
Medical Devices(3)
 
 
1,497

 
1,579

 
(5.2
)
Segment earnings before provision for taxes
 
 
4,569

 
5,793

 
(21.1
)
Less: Expense not allocated to segments (4)
 
 
147

 
312

 
 

Worldwide income before tax
 
 
$
4,422

 
5,481

 
(19.3
)%

(1) Includes a gain of $0.3 billion related to the Company's previously held equity investment in Ci:z Holdings Co., Ltd. (Dr. Ci: Labo) Includes amortization expense of $0.1 billion and $0.1 billion in the fiscal first quarters of 2019 and 2018, respectively.
 
(2) Includes an in-process research and development expense of $0.9 billion related to the Alios asset, litigation expense of $0.3 billion and an unrealized gain on securities of $0.1 billion in the fiscal first quarter of 2019. Additionally, the fiscal first quarter of 2019 includes increased research and development expense primarily $0.3 billion related to an upfront payment to argenx and increased investment to advance the pipeline. Includes Actelion acquisition related costs of $0.1 billion in the fiscal first quarter of 2018. Includes amortization expense of $0.8 billion and $0.8 billion in the fiscal first quarters of 2019 and 2018, respectively.
(3) Includes a restructuring related charge of $0.1 billion and $0.1 billion in the fiscal first quarters of 2019 and 2018, respectively. Includes litigation expense of $0.1 billion in the fiscal first quarter of 2019. Includes amortization expense of $0.2 billion and $0.3 billion in the fiscal first quarters of 2019 and 2018, respectively.
(4) Amounts not allocated to segments include interest income/expense and general corporate income/expense.
Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas
SALES BY GEOGRAPHIC AREA
 
 
 
Fiscal First Quarters Ended
(Dollars in Millions)
 
 
March 31, 2019
 
April 1, 2018
 
Percent Change
United States
 
 
$
10,129

 
9,951

 
1.8
 %
Europe
 
 
4,609

 
4,797

 
(3.9
)
Western Hemisphere, excluding U.S.
 
 
1,503

 
1,567

 
(4.1
)
Asia-Pacific, Africa
 
 
3,780

 
3,694

 
2.3

Total
 
 
$
20,021

 
20,009

 
0.1
 %